Resources

Downloadable Resources

Access white papers, briefs and other client resources

Explore Now

New On the US-Rx Care Blog

Discover industry insights and the latest news from US-Rx

Explore Now

Upcoming Events & Webinars

Explore webinars and other events from US-Rx

Explore Now

Industry Insights & Resources

US-Rx Care is proud to be an industry leader and provide insights and resources to help clients navigate the ins and outs of pharmacy risk management. Explore some of our resources below, or schedule a call to learn more about what we do and the benefits for plan sponsors and plan enrollees.

Downloadable Resources

Fiduciary Mindset White Paper

White Paper:
The New Era of Class Action CAA Lawsuits

National Alliance Playbook

National Alliance Playbook:
Addressing Pharmacy Benefit Management Misalignment.

Fiduciary Mindset White Paper

White Paper:
Pharmacy Risk Management with a Fiduciary Mindset.

Specialty Savings Mcckup

White Paper:
Critically important strategies to reduce specialty spend.

CAA Quick Guide

Industry Brief:
CAA Quick Guide for self-insured employers.

CAA White Paper

White Paper:
A self-insured employers’ guide to Navigating CAA Compliance.

Common Myths

Industry Insights:
Busting common myths related to benefits management.

Overcoming PBM Challenges White Paper

White Paper:
2024 employer action plan for overcoming PBM challenges.

The Problem With PBM Rebate Guarantees White Paper

White Paper:
The Problem With PBM Rebate Guarantees

Everything US-Rx Care promised has come true, with no loss in care. The less we pay, the less cost share that employees have to pay on prescriptions"

Explore Case Studies & Client Success Stories.

Explore the Latest News and Resources from US-Rx Care

Study Predicts 8% Group Health Plan Cost Increase for 2025

Study Predicts 8% Group Health Plan Cost Increase for 2025

A new study predicts that group health insurance costs will jump 8% in 2025, on par with what American employers have experienced this year and in 2023.

The higher rates reflect the costs borne by health insurers, which are seeing more claims for care that was postponed during the COVID-19 pandemic and a steady rise in the cost of pharmaceuticals as more innovative and effective drugs come to market, according to the study. There are also a few new cost drivers, which are counterbalanced by the potential for savings thanks to some new developments.

read more